TMLP yields 2.06% · PFE yields 6.20%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, TMLP + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TMLP + PFE for your $10,000?
TMLP provides exposure to the MLP universe through a market cap-weighted index of US master limited partnerships (MLPs) and limited liability companies. MLPs are publicly listed partnerships that focus on the transportation, production, processing, or storage of energy commodities. To be included in the index, the company must be 1) in the domiciled and traded in the US, 2) have at least $200 million USD in market cap and 3) maintain an average of $175 million USD in market-cap for a minimum of 20 trading days prior to the rebalance reference date. The fund intends to seek exposure to the underlying index by primarily investing in total return swaps that reference the components of the underlying index. It may, additionally, directly hold the securities of the index constituents up to 25% of its total assets only. A 7.5% capping is also applied to individual positions alongside a 15% limit to securities of an MLP Affiliate family. The index is rebalanced on a quarterly basis.
Full TMLP Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.